At the news
? BEARISHIMPACT 6/10 6-K filed Aug 4, 2026 at 07:00 ET
BioNTech reported Q2 2026 revenues of €105.6M, down 60% YoY from €260.8M, driven by declining COVID-19 vaccine demand. The company posted an IFRS net loss of €820.8M (vs. €386.6M loss in Q2 2025) and cut full-year 2026 revenue guidance to €1.6-1.9B from €2.0-2.3B. Oncology pipeline progress was highlighted with 14 ongoing pivotal trials, but the revenue miss and guidance cut dominate the near-term outlook.
- Q2 2026 revenues of €105.6M, down 59.5% from €260.8M in Q2 2025
- IFRS net loss of €820.8M in Q2 2026, more than doubling from €386.6M loss in Q2 2025
- Full-year 2026 revenue guidance cut to €1.6-1.9B from prior €2.0-2.3B
- Adjusted R&D expenses guidance lowered to €2.0-2.3B from €2.2-2.5B
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access